251
Participants
Start Date
September 26, 2013
Primary Completion Date
January 6, 2016
Study Completion Date
January 6, 2016
BYM338/bimagrumab
BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Placebo
Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Novartis Investigative Site, Brussels
Novartis Investigative Site, St Leonards
Novartis Investigative Site, Copenhagen
Novartis Investigative Site, Edegem
Novartis Investigative Site, Cauldfield
Novartis Investigative Site, Nedlands
Novartis Investigative Site, Zurich
Novartis Investigative Site, Ghent
Novartis Investigative Site, Milan
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Brescia
Novartis Investigative Site, Miami
Novartis Investigative Site, Padua
Novartis Investigative Site, Columbus
Novartis Investigative Site, Kansas City
Novartis Investigative Site, Paris
Novartis Investigative Site, Dallas
Novartis Investigative Site, Houston
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Orange
Novartis Investigative Site, Sacramento
Novartis Investigative Site, Portland
Novartis Investigative Site, Messina
Novartis Investigative Site, Boston
Novartis Investigative Site, Boston
Novartis Investigative Site, Rome
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Sendai
Novartis Investigative Site, Osaka
Novartis Investigative Site, Tokushima
Novartis Investigative Site, Kodaira
Novartis Investigative Site, Wakayama
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Leiden
Novartis Investigative Site, Salford
Novartis Investigative Site, London
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY